i3 Health

05/02/2026

New Virtual Tumor Board: Best practices for HER2-mutant non–small cell lung cancer in the community setting, covering biomarker testing workflows, multidisciplinary coordination, and toxicity management.

Watch now and then claim your or :

1 like. "HER2-Mutant NSCLC Virtual Tumor Board: Applying Advances and Best Practices in the Community Setting"

05/02/2026

Who coordinates care, manages symptoms, educates families, and stays present through hard days and hopeful ones? Oncology nurses. This month, we celebrate the impact you make across the cancer care continuum.

05/01/2026

Is a PYP scan enough to diagnose amyloid? Not by itself. Learn what to order, what to rule out, and how to identify hereditary -CM sooner. Earn 1.0 credit: https://bit.ly/4ntAv8Z

05/01/2026

This , we are proud to spotlight the expert faculty leading From Mutation to Management: Practical Nursing Strategies in HER2-Mutant NSCLC at .

Dr. Zofia Piotrowska, MD, MHS, Harvard Medical School and Massachusetts General Hospital, specializes in lung cancer treatment and leads clinical trials investigating novel therapies for NSCLC.

Dr. Victoria Sherry, DNP, ANP-BC, AOCNP®, Penn Medicine - Abramson Cancer Center, is a leader in symptom and toxicity management in lung cancer and is passionate about mentoring the next generation of oncology nurses.

Dr. Soo-Ryum (Stewart) Yang, MD, Memorial Sloan Kettering Cancer Center, focuses on predictive biomarkers in NSCLC, molecular drivers of lung adenocarcinoma, and liquid biopsy testing.

Join these distinguished faculty members at in person or via Zoom for this NCPD-approved symposium. Earn 1.5 ANCC credits while gaining practical strategies for HER2-mutant NSCLC care.

Join us at ONS: https://bit.ly/4cw58Go

Can’t make it to ONS in person? Join us virtually via Zoom: https://bit.ly/4et5mAI

04/30/2026

are rare and aggressive, and diagnostic delays can happen, especially on small biopsies. Learn practical ways to reduce misclassification and support timely treatment decisions. Earn 0.75 credit:

Expert Insights on Diagnosing and Treating Extrapulmonary Neuroendocrine Carcinomas (EP-NECs)

04/30/2026

Groundbreaking prostate cancer data from 2026 includes advancements in combination therapies, PSMA-targeted T-cell engagers, and treatment intensification strategies.

Dr. Stephen Freedland and Dr. Alicia Morgans recap the findings shaping the future of care:

ASCO Genitourinary Cancers Symposium 2026: Prostate Cancer Recap

04/30/2026

Awareness Month 2025 brought attention to the importance of early detection, multidisciplinary care, and patient-centered treatment. Dr. Seetharamu, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, highlighted both progress in HPV-related cancers and the ongoing need for better support in recovery and rehabilitation.

Stay informed: https://ow.ly/LmHp50YQJ67

04/29/2026

Join us at for an in-person, NCPD-approved symposium: From Mutation to Management: Practical Nursing Strategies in HER2-Mutant NSCLC.

This symposium will provide clarity on HER2 mutations, actionable strategies for toxicity monitoring, and interactive learning with expert faculty. Earn 1.5 ANCC credits for participation.

Register now: https://bit.ly/4cw58Go

04/29/2026

Your Update: Here’s what’s new!

Not attending ONS? Join us from home for this NCPD-approved satellite symposium! From Mutation to Management: Practical Nursing Strategies in HER2-Mutant NSCLC: bit.ly/49biwyJ

Patient Experience Week: How Small Moments Make a Big Impact: https://bit.ly/4vTkrSl

Measuring Clinical Trial Representation in the Era of Precision Medicine: https://bit.ly/4ulAFCn

04/28/2026

: When primary care providers evaluate neuropathy, rapid progression or worsening weakness over a short timeline should not be overlooked. These signs may indicate and warrant referral to neurology.

This activity reviews strategies for earlier detection and individualized management to improve patient outcomes: https://bit.ly/44com0n

04/27/2026

is no longer the "go home and get your affairs in order" diagnosis. With over 100 compounds in development and new multidisciplinary strategies, there is reason for optimism. Claim 1.0 credit: https://www.youtube.com/watch?v=4GwCdTpsrT8&t=2s

04/27/2026

Stay informed on the latest advancements in care with the Oncology Data Advisor podcast!

Don’t miss out! Listen to the latest episode now: https://soundcloud.com/oncologydataadvisor